Pierre Fabre Laboratories. (1/10/24). "Press Release: Hervé Hoppenot, Incyte CEO, Is Appointed on the Board of Pierre Fabre Laboratories". Castres.

	Organisation	Pierre Fabre S.A.
	Group	Pierre Fabre (Group)
	Product	pharmaceutical
	Product 2	Ebvallo™
	Person	Hoppenot, Hervé (Incyte 201401– CEO before Novartis President Oncology)
	Person 2	Doliveux, Roch (UCB 200602 CEO)

President and CEO of the biotechnology company Incyte since 2014, Hervé Hoppenot will bring his extensive pharmaceutical expertise to the Board of Directors of Pierre Fabre Laboratories, particularly in the field of oncology. His appointment comes at a time when Pierre Fabre is preparing to market in the US its allogeneic immunotherapy Ebvallo® which has just been awarded the prestigious Prix Galien for its therapeutic innovation. Ebvallo®’s Biologics License Application will be submitted to the Food & Drug Administration (FDA) in the second quarter of 2024.

Hervé Hoppenot, 63, a dual French American citizen, has spent most of his career in the United States. He occupied successively the positions of Vice President (VP) for the US Oncology franchise at Aventis (2000-2005), Sales Director USA and Executive VP at Novartis (2006-2010) and President of the Novartis Oncology Global franchise (2010-2014).

Hervé Hoppenot joined Incyte Corp. in 2014 as President and Chief Executive Officer, a young biotechnology company that he gradually transformed into a major player in onco-hematology. Incyte generated $3.4 billion in revenue in 2022 and invests over 40% of its revenue annually in Research & Development.

Hervé Hoppenot will also join the Strategic Committee of the Board of Directors.

Roch Doliveux, Chairman of the Board, welcomed the appointment:
“Together with Pierre-Yves Revol, Chairman of the Group's controlling holding company, we are delighted to welcome Hervé Hoppenot, whose expertise and international experience will be invaluable in the further development of our oncology activities. These have more than doubled since 2019, they now account for over 40% of our Medical Care revenues and represent our first growth potential.”

Hervé Hoppenot declared himself:
“Happy and proud to join the Board of an independent company that innovates across the entire spectrum of therapy and care for patients affected by cancer, from prevention to new targeted therapies. I'm looking forward to discovering the original model of a company which is owned by a government-recognized public-interest foundation and whose humanist values resonates strongly with me.”

About Pierre Fabre Laboratories

Pierre Fabre Laboratories is a leading French medical and beauty care company with 4 decades of experience in innovation, development, manufacturing, and commercialization in oncology. The company dedicated about 80% of its R&D spendings to oncology in 2022 with a focus on targeted therapies. Its current commercial portfolio in oncology covers colorectal, breast and lung cancers, melanoma, hematology, and pre-cancerous skin conditions like actinic keratosis.

In 2022, Pierre Fabre Laboratories posted 2.7 billion euros in revenues, 69% of which came from international sales in 120 countries. Established in the South-West of France since its creation in 1962, the Group manufactures 90% of its products in France and employs some 9,600 people worldwide. The company is 86%-owned by the Pierre Fabre Foundation, a government-recognized public-interest foundation, and by its own employees through an international employee stock ownership plan. Pierre Fabre Laboratories’ sustainability policy has been assessed by the independent AFNOR Certification body at the "Exemplary" level of its CSR label (ISO 26 000 standard for sustainable development).

Further information about Pierre Fabre Laboratories can be found at www.pierre-fabre.com, @PierreFabre

Presse Contact

Laboratoires Pierre Fabre
Caroline Perdrix
caroline.perdrixr@pierre-fabre.com

Record changed: 2024-03-27